Posology : מינונים

4.2   Posology and method of administration

Recommended therapy is one drop in the affected eye twice a day.
If needed, ‘V-OPTIC 0.25%’ may be used with other agent(s) for lowering intra-ocular pressure. The use of two topical beta-adrenergic blocking agents is not recommended (see 4.4 ‘Special warnings and precautions for use’).

Intra-ocular pressure should be reassessed approximately four weeks after starting treatment because response to ‘V-OPTIC 0.25%’ may take a few weeks to stabilise.

Provided that the intra-ocular pressure is maintained at satisfactory levels, many patients can then be placed on once-a-day therapy.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

Transfer from other agents
When another topical beta-blocking agent is being used, discontinue its use after a full day of therapy and start treatment the next day with one drop of ‘V-OPTIC 0.25%’ in each affected eye twice a day.


When transferring a patient from a single anti-glaucoma agent other than a topical beta- blocking agent, continue the agent and add one drop of ‘V-OPTIC 0.25%’ in each affected eye twice a day. On the following day, discontinue the previous agent completely, and continue with the ‘V-OPTIC 0.25%’.

Use in the elderly: there has been wide experience with the use of timolol maleate in elderly patients. The dosage recommendations given above reflect the clinical data derived from this experience.

Paediatric Population:
Safety and effectiveness in pediatric patients have not been established.